Rare Disease Focus: Kidney and Urinary Diseases ++++++

CLINICAL PERSPECTIVES One-Year Phase 3 Data Testing Empaveli (pegcetacoplan) in Patients with C3G and IC-MPGN https://checkrare.com/one-year-phase-3-data-testing-empaveli-pegcetacoplan-in-patients-with-c3g-and-ic-mpgn/ Carla Nester, MD, Professor of Pediatrics-Nephrology at the University of Iowa, discusses one-year phase 3 data of Empaveli (pegcetacoplan) for treatment of C3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN). Interim Results From Study of Mezagitamab for the Treatment of IgA Nephropathy https://checkrare.com/interim-results-from-study-of-mezagitamab-for-the-treatment-of-iga-nephropathy/ Jonathan Barratt, Mayer Professor of Renal Medicine at the University of Leicester, discusses interim results from a study testing mezagitamab for the treatment of immunoglobulin A (IgA) nephropathy. Data from the DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis https://checkrare.com/data-from-the-duplex-study-of-sparsentan-in-focal-segmental-glomerulosclerosis/ Michelle Rheault, MD, Pediatric Nephrologist at the University of Minnesota, discusses data from the DUPLEX study testing sparsentan to treat patients with focal segmental glomerulosclerosis (FSGS). ORIGIN 3 Clinical Trial Evaluating Atacicept in Adults With IgA Nephropathy https://checkrare.com/origin-3-clinical-trial-evaluating-atacicept-in-adults-with-iga-nephropathy/ Richard Lafayette, MD, Professor of Medicine at Stanford University, discusses the ORIGIN clinical trial evaluating atacicept in adults with IgA nephropathy (IgAN). Long-Term Data From the AQUARIUS Study of Avacopan in Patients With GPA and MPA https://checkrare.com/long-term-data-from-the-aquarius-study-of-avacopan-in-patients-with-gpa-and-mpa/ Naomi Patel, MD, MPH, Rheumatologist at Massachusetts General Hospital, discusses long-term data from the AQUARIUS study of avacopan in patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Results from the ElevAATe Clinical Trial of Efdoralprin Alfa for Patients With AAT Deficiency https://checkrare.com/results-from-the-elevaate-clinical-trial-of-efdoralprin-alfa-for-patients-with-aat-deficiency/ Alaa Hamed, MD, Global Head of Medical Affairs Rare Diseases at Sanofi, discusses results from the ElevAATe clinical trial of efdoralprin alfa for the treatment of patients with alpha-1 antitrypsin deficiency (AATD).